Perrigo Pharma International Designated Activity Co. v. Mead Johnson & Co. LLC

CourtDistrict Court, S.D. New York
DecidedApril 1, 2024
Docket1:23-cv-00008
StatusUnknown

This text of Perrigo Pharma International Designated Activity Co. v. Mead Johnson & Co. LLC (Perrigo Pharma International Designated Activity Co. v. Mead Johnson & Co. LLC) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Perrigo Pharma International Designated Activity Co. v. Mead Johnson & Co. LLC, (S.D.N.Y. 2024).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK PERRIGO PHARMA INTERNATIONAL DESIGNATED ACTIVITY CO., Plaintiff, OPINION & ORDER – against – 23-cv-00008 (ER) MEAD JOHNSON & CO. LLC, Defendant. RAMOS, D.J.: �is action arises from Perrigo Pharma International Designated Activity Company’s allegations that Mead Johnson & Co. LLC refused to perform its contractual duties to package infant formula manufactured by Perrigo. Before the Court is Mead Johnson’s motion to dismiss Perrigo’s amended complaint. Doc. 96. For the reasons set forth below, the motion is GRANTED IN PART and DENIED IN PART. I. BACKGROUND A. �e Parties Perrigo is a manufacturer of infant formula. Doc. 72 ¶ 15 (“Am. Compl.”). It is incorporated in Ireland and its principal place of business is Dublin, Ireland. Id. ¶ 8. Mead Johnson is a limited liability company organized under the laws of Delaware. Id. ¶ 9. Its sole member, Mead Johnson Nutrition Company, is a corporation incorporated under the laws of Delaware and its principal place of business is Evansville, Indiana. Id. ¶¶ 9–10. Mead Johnson manufactures, packages, and sells its own infant formula. Id. ¶¶ 85, 87, 92. B. Perrigo’s Infant Formula Business Perrigo manufactures two types of infant formula: “regular” formula and extensively hydrolyzed (“EH”) formula, which is suitable for infants allergic to cow’s milk. Id. ¶ 4. Perrigo manufactures both types of infant formula at a facility in Covington, Ohio (the “Ohio Facility”). Id. ¶¶ 15–16. Perrigo cannot manufacture both types of formula simultaneously. Id. ¶ 17. Before EH formula can be manufactured, Id. To minimize these shutdowns, Perrigo manufactures EH formula in intensive “campaigns” lasting Id. Infant formula is perishable, so Perrigo must have it packaged promptly after production in order to avoid spoilage. Id. ¶ 18. �us, although Perrigo generally seeks to manufacture as much formula as possible, its production is constrained by its ability to have the formula packaged. Id. To sell its formula in the U.S. market, Perrigo must obtain clearance from the Food and Drug Administration (“FDA”). Id. ¶ 19. �is requires having its formula packaged at FDA-approved packaging sites. Id. Because the Ohio Facility lacks the ability to package infant formula, Perrigo must ship the formula produced there elsewhere to have it packaged. Id. ¶ 20. On March 14, 2019, Perrigo and Maple Island, Inc., entered into a Master Services Agreement (the “MSA”) under which Maple Island agreed to package Perrigo’s infant formula at an FDA-approved packaging facility in Wanamingo, Minnesota (the “Wanamingo Facility”). Id. ¶¶ 20, 22. Id. ¶ 20.

Id. ¶ 21. so that EH formula can be packaged. Id. On March 27, 2020, Perrigo and Maple Island entered into two agreements amending and supplementing the MSA: an Addendum to the MSA (the “Addendum”) and an Amendment to the MSA (the “Amendment”). Id. ¶ 23. In early 2021, Mead Johnson purchased the Wanamingo Facility from Maple Island. Id. ¶ 24. Under the MSA, Maple Island could not assign its agreements with Perrigo to Mead Johnson without Perrigo’s consent. Id. �us, on January 20, 2021, Perrigo, Mead Johnson, and Maple Island entered into an agreement pursuant to which (1) Maple Island assigned to Mead Johnson its rights and obligations under the MSA, the Addendum, and the Amendment, and (2) Perrigo consented to the assignment (the “Consent,” and collectively with the MSA, the Addendum, and the Amendment, the “Agreement”). Id. ¶ 25. C. �e Agreement’s Terms The Consent Out of concern that Mead Johnson, a major infant formula manufacturer, was purchasing a critical link in Perrigo’s infant formula supply chain, Perrigo negotiated for additional provisions in the Consent, two of which are relevant here. Id. ¶¶ 25–26. First, Perrigo conditioned its consent to assignment on Mead Johnson making an annual packaging capacity commitment—and agreeing to accept purchase orders up to those capacity commitments—for Perrigo’s regular and EH formula in 2021, 2022, and 2023. Id. ¶ 26. Second, Perrigo conditioned its consent on extending the notice period in the MSA’s termination-for-convenience provision. Id. ¶ 27.

Id.

Id. Mead Johnson’s Packaging Obligations Under the terms of the Agreement, to order packaging services, Perrigo must send written purchase orders to Mead Johnson. Id. ¶ 30. Purchase orders need not be in any particular format. Id. I | 12.220 2 sso spect delivery date in a purchase order, which Mead Johnson must meet so long as the delivery date ' i _ from the date of the purchase order.” Id. § 34. Perrigo alleges that under the express terms of the Agreement, Mead Johnson is required to (1) accept Perrigo’s purchase orders, (2) package the quantity of formula ordered, and (3) deliver the packaged formula to Perrigo. Jd. Ff 28-34.

«5 (emphasis omitted). Schedule 1 to the MSA confirms Mead Johnson’s obligation to accept purchase orders for EH formula packaging. Jd. § 32. It provides: ee

ee Id. (emphasis omitted). Schedule 2 to the MSA includes a parallel provision that confirms Mead Johnson’s obligation to accept purchase orders for regular formula packaging. Jd. ¥ 33. Furthermore, section 3.3 of the MSA provides:

1 The MSA provides:

Am. Compl. § 30 (emphasis omitted). 2 The MSA provides:

Am. Compl. § 34 (omission in original) (emphases omitted).

Id. § 29 (emphases omitted). The MSA defines

:--.3: alteration 1n original). The sole exception to Mead Johnson’s duty to package the formula is if Perrigo has not sent Mead Johnson a sufficient amount of infant formula to package.* Id. 4 34. The Agreement allows for minor variations from the terms of purchase orders. Jd. 436. For regular formula, Mead Johnson is expected ia

3. Ihe No Waiver Provision The MS. nc! 00:91 25. 1 provision contains two clauses. Jd. The first clause (the a) states:

3 The Addendum provides:

Am. Compl. § 35 (emphasis omitted). * Perrigo submitted Doc. 9-1 in connection with its application for a temporary restraining order and preliminary injunction. It includes the MSA, the Addendum, the Amendment, and the Consent. The Court may consider these documents because they are incorporated by reference in and integral to the amended complaint. DiFolco v. MSNBC Cable L.L.C., 622 F.3d 104, 111 (2d Cir. 2010).

Id. The second clause (the ee) states:

Id. 4. The Limitation of Liability Provision The MSA also includes a limitation of liability provision. Jd. at 19-20. It provides that:

Id. (capitalization omitted). D. The Parties’ Performance of the Agreement At all relevant times, Perrigo sent written purchase orders for packaging services to Mead Johnson in a spreadsheet format. Am. Compl. § 39. Each purchase order specified the quantities of formula to be packaged. Jd. Under the parties’ longstanding, accepted practice, Perrigo’s purchase orders specified the date that Mead Johnson was to commence packaging—as opposed to delivering—each batch of formula. Jd. Due to variations in the time required to package formula, perform quality testing, and prepare release paperwork, the date Mead Johnson released packaged formula to Perrigo varied, but it was typically after

packaging was completed. Id. According to Perrigo, a failure by Mead Johnson to deliver packaged formula within this time frame is a material breach of the Agreement. Id. Perrigo alleges that it has a clear contractual right to require Mead Johnson to perform under the Agreement by the letter of Perrigo’s purchase orders. Id. ¶ 40. Since Mead Johnson purchased the Wanamingo Facility, however, Perrigo has tried to work with Mead Johnson to select mutually agreeable packaging dates. Id. Perrigo has also made an effort to give Mead Johnson several months’ notice of planned EH campaigns. Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Foman v. Davis
371 U.S. 178 (Supreme Court, 1962)
Flagg Bros., Inc. v. Brooks
436 U.S. 149 (Supreme Court, 1978)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
DiFolco v. MSNBC Cable L.L.C.
622 F.3d 104 (Second Circuit, 2010)
Fischer & Mandell LLP v. Citibank, N.A.
632 F.3d 793 (Second Circuit, 2011)
Halebian v. Berv
644 F.3d 122 (Second Circuit, 2011)
M/a-Com Security Corporation v. Francesco Galesi
904 F.2d 134 (Second Circuit, 1990)
Koch v. Christie's International PLC
699 F.3d 141 (Second Circuit, 2012)
Cruz v. FXDirectDealer, LLC
720 F.3d 115 (Second Circuit, 2013)
Schonberger v. Serchuk
742 F. Supp. 108 (S.D. New York, 1990)
Dalton v. Educational Testing Service
663 N.E.2d 289 (New York Court of Appeals, 1995)
Metropolitan Life Insurance v. Noble Lowndes International, Inc.
643 N.E.2d 504 (New York Court of Appeals, 1994)
Camofi Master LDC v. College Partnership, Inc.
452 F. Supp. 2d 462 (S.D. New York, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
Perrigo Pharma International Designated Activity Co. v. Mead Johnson & Co. LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/perrigo-pharma-international-designated-activity-co-v-mead-johnson-co-nysd-2024.